Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Zhihao, Zha"'
Autor:
Peng He, Bing Zhang, Yuan Zou, Yan Zhang, Zhihao Zha, Yali Long, Jia Qiu, Wanqing Shen, Xiaoping Lin, Zhoulei Li, Xiangsong Zhang
Publikováno v:
Translational Oncology, Vol 14, Iss 5, Pp 101055- (2021)
L-ascorbic acid (AA) was reported to have an anti-cancer effect over 40 years. In recent years, several ongoing clinical trials are exploring the safety and efficacy of intravenous high-dose AA for cancer treatment. The lack of appropriate imaging mo
Externí odkaz:
https://doaj.org/article/7d01b9096f9849fcbee7f3474534c7b4
Autor:
Haiyan Hong, Zhihao Zha, Ruiyue Zhao, Yang Luo, Wenbin Jin, Linlin Li, Ran Wang, Li Yan, Hui Wang, Karl Ploessl, Jinping Qiao, Lin Zhu, Hank F. Kung
Publikováno v:
Molecular Pharmaceutics. 20:2159-2169
Publikováno v:
Royal Society Open Science, Vol 6, Iss 11 (2019)
HBED-CC (N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylene diamine-N,N'-diacetic acid, L1) is a common bifunctional chelating agent in preparation of 68Ga-radiopharmaceuticals. Due to its high stability constant for the Ga3+ complex (logKGaL = 38.5)
Externí odkaz:
https://doaj.org/article/172e041be94e4a4599a5991cc41a03ee
Autor:
Zhihao Zha, Seok Rye Choi, Linlin Li, Ruiyue Zhao, Karl Ploessl, Xinyue Yao, David Alexoff, Lin Zhu, Hank F. Kung
Publikováno v:
Journal of Medicinal Chemistry. 65:13001-13012
Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis and radionuclide therapy of prostate cancer. This study reports conversion of a previously reported
Autor:
Yali Long, Chang Yi, Renbo Wu, Yuying Zhang, Bing Zhang, Xinchong Shi, Xiangsong Zhang, Zhihao Zha
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging.
Kit-based preparation of [68Ga]Ga-P16-093 (PSMA-093) using different commercial 68Ge/68Ga generators
Autor:
Haiyan Hong, Guochang Wang, Karl Ploessl, Zhihao Zha, Jie Zang, Zhaohui Zhu, Lin Zhu, Hank F. Kung
Publikováno v:
Nuclear Medicine and Biology. :1-9
Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [18F]AlF-P16-093
Publikováno v:
Bioconjugate Chemistry. 32:1017-1026
Prostate-specific membrane antigen (PSMA)-targeted radioligands have played an increasing role in the diagnosis of prostate cancer. [68Ga]Ga-P16-093 is a PSMA-targeting agent for positron emission tomography imaging, currently under a Phase 2 clinica
Publikováno v:
Nuclear Medicine and Biology. 92:97-106
Introduction Since the approval of three 18F labeled β-amyloid-targeting PET imaging agents, Amyvid (florbetapir f18, AV-45), Neuraceq (florbetaben f18, AV-1) and Vizamyl (flutemetamol f18, F-PIB), they have increasingly been employed to assist diff
Publikováno v:
Molecular Pharmaceutics. 17:4589-4602
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells and therefore is an attractive target for prostate cancer diagnosis and radionuclide therapy. Recently, published results from clinical studies using a new PSMA-targe
Autor:
Kyle J. Labban, Karl Ploessl, Janet S. Reddin, Robert K. Doot, Erin K. Schubert, Hank F. Kung, Seok Rye Choi, David Alexoff, Hsiaoju Lee, Lin Zhu, Hwan Lee, Daniel A. Pryma, Zhihao Zha, Margaret E. Daube-Witherspoon, Zehui Wu, Joel S. Karp, Anthony J. Young
Publikováno v:
Nucl Med Biol
INTRODUCTION: [(68)Ga]Ga-P15-041 ([(68)Ga]Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer that can be generator-produced. We undertook a Phase 0/I clinical trial to assess its potential for imaging bone metastases in prostate cancer including